Healthcare & Life Sciences

Latham offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet client needs.

Why Latham

Latham’s cross-disciplinary healthcare and life sciences team delivers insightful, practical guidance and sophisticated representation to a full spectrum of companies across the globe, on every type of transaction or dispute a company may face. Many of us hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.

We regularly navigate commercial and regulatory issues related to the Food and Drug Administration, the Patent Trial and Appeals Board, the European Medicines Agency, the European Commission, and other state, and federal agencies in the US and across Europe.

We deliver:

  • The right team. We work with companies at every stage of development, from fast-growing startups to mature public companies, in virtually every sector and subsector of the industry – including healthcare services, biotechnology, medtech and medical devices. With an outstanding global platform, we can scale our client teams to meet client needs — whether that means drawing on best-of-the-best capabilities in public company representation, M&A, capital markets, regulatory advice or IP and securities litigation.
  • Insight. Our broad client base and on-the-ground presence in the world’s healthcare and life sciences hubs afford us an expansive view of the commercial, scientific, regulatory, and political trends shaping the markets in which clients operate. We know how traditional regulatory regimes work, and quickly set the bar for successful strategies in dynamic and uncertain regulatory landscapes.
  • Results. By leveraging decades of experience and a culture of innovation, we have developed an impressive track record navigating many of the industry’s largest, most complex, and most consequential deals through commercial and regulatory issues, as well as winning precedent-setting litigation and trials.


Our Experience

Awards & Rankings

  • 10 Latham Lawyers Named 2021 Rising Stars - May 31, 2021
  • Latham & Watkins Wins Five Europe LMG Life Sciences Awards 2021 - May 12, 2021
  • Partner George Klidonas Named to Outstanding Young Restructuring Lawyers List - April 20, 2021
  • Latham Named IP Transactions Firm of the Year - April 14, 2021
  • Latham Ranked Among Top Lawyers in North America Across Disciplines - March 17, 2021

A best-in-market corporate team with a sterling reputation for its counsel on M&A transactions, public and private securities offerings, and strategic partnerships. Acts for early-stage and long-established companies as well as banks and financiers. Contentious practice with expertise in handling everything from white-collar investigations to intellectual property disputes. 

Chambers 2020 USA


Drug and Device Pricing and Reimbursement Landscape: Legal and Policy Trends Under the Biden AdministrationWebcast – FDA Regulatory Updates and 2020 Outlook for Vaping and Cannabis-Derived Substances

Media Coverage

2 Years In, Tech Division Makes FTC 'Far More Efficient'Healthcare & Life Sciences Trailblazer: Nathan AjiashviliAstellas Wins Sole Ownership of Stem-Cell Production Patents


Latham & Watkins Advises the Underwriters in Lyell Immunopharma’s US$425 Million IPOLatham & Watkins Advises Novo Holdings on BBI Group AcquisitionLatham & Watkins Advises Fractyl Health in its US$100 Million Series F Financing

Thought Leadership

Healthcare & Life Sciences: Drug Pricing Digest Digital Health 2021Healthcare & Life Sciences: Drug Pricing Digest

Webcasts & Podcasts

Podcast – Healthcare Tech: How Are Licensing Agreements Bridging the Industry Divide?Podcast – Healthcare Tech: How Will the FDA Regulatory Framework Adapt to AI?A Look Ahead at the Biden Administration’s Regulatory and Enforcement Priorities